Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL versus PROPRANOLOL HYDROCHLORIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL versus PROPRANOLOL HYDROCHLORIDE INTENSOL.
Labetalol vs PROPRANOLOL HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure; also suppresses renin release and reduces CNS sympathetic outflow.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
Initial: 40 mg orally twice daily; maintenance: 120-240 mg/day in 2-3 divided doses. Maximum: 640 mg/day. For hypertension, start 40 mg twice daily, increase gradually.
None Documented
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Terminal elimination half-life is 3–6 hours, but clinical effects (e.g., beta-blockade) persist longer due to prolonged receptor occupancy. Half-life may increase in hepatic impairment.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Primarily hepatic metabolism (>99%) with <1% excreted unchanged in urine. Metabolites are excreted renally. Fecal elimination is minimal.
Category A/B
Category C
Alpha/Beta-Blocker
Beta-Blocker